GlassScriptPhysician profile
Jason M Goldman
NPI 1184610040
$1,857.43
in general payments reported to CMS, 2019-2025
22 companies · $76.40 in 2025
The $76.40 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $148 · 2022: $108 · 2023: $593 · 2024: $443 · 2025: $76.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,112.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $483.60 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $201.60 | 2019-2024 | Wegovy |
| Amgen INC. | $176.47 | 2019-2024 | Repatha, Otezla |
| Lilly USA, LLC | $175.56 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $108.38 | 2019-2024 | Xarelto |
| Heartflow, INC. | $108.30 | 2022 | |
| Sanofi Pasteur INC. | $73.84 | 2019-2024 | |
| Boston Scientific Corporation | $70.31 | 2024 | Watchman Flx |
| Abbvie INC. | $69.93 | 2023-2025 | |
| Gilead Sciences, INC. | $66.01 | 2019-2024 | |
| Pfizer INC. | $60.98 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $58.46 | 2023-2024 | Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $39.19 | 2020-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Esperion Therapeutics, INC. | $25.69 | 2024 | Nexletol |
| Alnylam Pharmaceuticals INC. | $24.25 | 2023 | Givlaari |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $19.65 | 2019 | |
| Amarin Pharma, INC. | $18.20 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $18.03 | 2019 | |
| Paratek Pharmaceuticals, INC. | $17.35 | 2023 | Nuzyra |
| Coastal Medical Technologies LLC | $15.28 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.05 | 2019 | |
| Allergan, INC. | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Goldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.